Chinese pharma firm selects cryogenic technology for plant expansion

A pharmaceutical company based in China has selected cryogenic technology developed by Linde to enhance its manufacturing capabilities and support company expansion plans.

SynTheAll Pharmaceuticals, a wholly owned subsidiary of WuXi Pharma Tech in Shanghai, has opted for Linde's CRYOHEAT system, which is provides the cooling and heating needs of process reaction vessels with a single unit.

According to Dr Eric Gu, vice president of manufacturing of WuXi PharmaTech, the system offers the company a complete turnkey solution from an advanced cryogenic system to gas and engineering services.

Under the contract terms, Linde will supply engineering services, maintenance support and associated bulk gases.

"We envisage good global demand for our cryogenic technology," said Joe Eschbach, head of marketing chemicals and energy with the Gases Division of The Linde Group. "Our intimate knowledge of the industry, the ability of our engineers to understand key customer issues and Linde's ability to provide custom solutions will drive future growth for us."

Linde's automated temperature control systems can significantly minimise maintenance and plant down time. They also offer increased accuracy in temperature control thereby improving efficiency, reducing energy consumption and preventing recurring operational issues such as ice formation. As a result, product yield and plant production capacity are greatly improved.